TABLE 3.
Registry variables | Number of patients |
Age | |
6–11 years; mean±sem | 26 (32%); 9.37±0.31 years |
≥12 years; mean±sem | 54 (68%); 14.70±0.22 years |
Overall mean±sem | 12.96±0.33 years |
Sex male/female | 49 (61%)/ 31 (39%) |
Ethnicity | Caucasians: 60 (75%); South-east Asians: 8 (10%); Black: 8 (10%); Mixed: 4 (5%) |
Parental history | Asthma: 38; Atopic eczema: 17; Allergic rhinitis: 33 |
Smoking history | Personal smoking: 2; Paternal smoking: 41; Maternal smoking: 12 |
Allergic asthma | |
Skin prick tests | Positive for perennial aeroallergen: 31; Positive for food allergen: 14 |
Specific IgE | Positive for perennial aeroallergen: 42; Positive for food allergen: 16 |
Highest blood eosinophils (cells·µL-1) in the 6 months prior to enrolment | ≥150: 41; <150: 11; Not recently assessed: 28 |
Highest blood IgE (IU·mL−1) in the 6 months prior to enrolment | ≥700: 21; 30–699: 26; <30: 5; Not recently assessed: 28 |
Highest FeNO (ppb) in the 6 months prior to enrolment | >35: 28; 20–35: 11; <20: 16; Not recently assessed: 25 |
Asthma control | |
ACT score | |
Median (IQR) ACT | 20 (16–23) |
Control by ACT | Poor control (<20): 26; Good control (≥20): 31; Not assessed: 23 |
GINA asthma control | Uncontrolled: 25; Partly controlled: 23; Well controlled: 32 |
≥2 exacerbations per year | Total:49; With good ACT/GINA control: 12 |
Suboptimal control by SPACE definition | 62 |
Best FEV1 (% predicted) in the 6 months prior to enrolment | <70%: 7; 70–79%: 10; 80–89%: 16; ≥90%: 46; Not recently assessed: 1 |
Data are presented as n (%) or n, unless otherwise stated. FeNO: exhaled nitric oxide fraction; ACT: asthma control test; IQR: interquartile range; GINA: Global Initiative for Asthma; SPACE: Severe Paediatric Asthma Collaborative in Europe; FEV1: forced expiratory volume in 1 s.